Patents by Inventor Melanie Janelle Bevill

Melanie Janelle Bevill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230029213
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 26, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20220289675
    Abstract: An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICALCO.,LTD.
    Inventors: Shuhei OTANI, Takayuki FUJITO, Naoko IMURA, Hideomi KIJIMA, Stephan D. PARENT, Melanie Janelle BEVILL, Courtney S. JOHNSON, Travis Lee HOUSTON
  • Patent number: 10098859
    Abstract: Disclosed herein are cocrystals of p-coumaric acid and nicotinamide. A 1:1 molar ratio and a 2:1 molar ratio of p-coumaric acid to nicotinamide are herein disclosed.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: October 16, 2018
    Assignee: AMRI SSCI, LLC
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • Patent number: 10004726
    Abstract: Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 26, 2018
    Assignee: AMRI SSCI, LLC
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • Patent number: 9982007
    Abstract: The present invention relates to a cocrystal of progesterone and a coformer selected from the group consisting of vanillic acid, benzoic acid, salicylic acid, cinnamic acid, and vanillin. The present invention also relates to a pharmaceutical composition comprising a cocrystal of the present invention and at least one pharmaceutically acceptable carrier. The present invention further relates to a method of supplementing progesterone in women. This method involves administering to a female subject in need thereof a pharmaceutical composition of the present invention.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: May 29, 2018
    Assignee: AMRI SSCI, LLC
    Inventors: Ekaterina Albert, Patricia Andres, Melanie Janelle Bevill, Jared Smit, Jennifer Nelson
  • Patent number: 9700545
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: July 11, 2017
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Publication number: 20170101433
    Abstract: The present invention relates to a cocrystal of progesterone and a coformer selected from the group consisting of vanillic acid, benzoic acid, salicylic acid, cinnamic acid, and vanillin. The present invention also relates to a pharmaceutical composition comprising a cocrystal of the present invention and at least one pharmaceutically acceptable carrier. The present invention further relates to a method of supplementing progesterone in women. This method involves administering to a female subject in need thereof a pharmaceutical composition of the present invention.
    Type: Application
    Filed: October 25, 2016
    Publication date: April 13, 2017
    Inventors: Ekaterina Albert, Patricia Andres, Melanie Janelle Bevill, Jared Smit, Jennifer Nelson
  • Patent number: 9512166
    Abstract: Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: December 6, 2016
    Assignee: AMRI SSCI, LLC
    Inventors: Ekaterina Albert, Patricia Andres, Melanie Janelle Bevill, Jared Smit, Jennifer Nelson
  • Publication number: 20160317507
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 3, 2016
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Publication number: 20160279115
    Abstract: Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 29, 2016
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • Patent number: 9359357
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 7, 2016
    Assignees: Salix Pharmaceuticals, Ltd., Alfa Wassermann S.P.A.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Patent number: 9314459
    Abstract: Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: April 19, 2016
    Assignee: AMRI SSCI, LLC
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • Publication number: 20160097142
    Abstract: Disclosed are processes for preparing cocrystals, including processes for scaling up of cocrystal formation, as well as scalable processes for preparing cocrystals. Also disclosed are processes for scaled-op preparation of pterostilbene, progesterone, p-coumaric, and minoxidil cocrystals. Minoxidil cocrystals, such as minoxidil:benzoic acid 1:1 monohydrate cocrystals are also disclosed herein.
    Type: Application
    Filed: August 10, 2015
    Publication date: April 7, 2016
    Applicant: AMRI SSCI, LLC
    Inventors: Melanie Janelle Bevill, Christopher Scott Seadeek, Ekaterina V. Albert, Petinka I. Vlahova, Richard James Ely, Patricia Andres
  • Patent number: 9181274
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: November 10, 2015
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Publication number: 20150299199
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: December 23, 2014
    Publication date: October 22, 2015
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Patent number: 9120766
    Abstract: Disclosed are processes for preparing cocrystals, including processes for scaling up of cocrystal formation, as well as scalable processes for preparing cocrystals. Also disclosed are processes for scaled-up preparation of pterostilbene, progesterone, p-coumaric, and minoxidil cocrystals. Minoxidil cocrystals, such as minoxidil:benzoic acid 1:1 monohydrate cocrystals are also disclosed herein.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: September 1, 2015
    Assignee: AMRI SSCI, LLC
    Inventors: Melanie Janelle Bevill, Christopher Scott Seadeek, Ekaterina V. Albert, Petinka I. Vlahova, Richard James Ely, Patricia Andres
  • Publication number: 20150216851
    Abstract: Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.
    Type: Application
    Filed: January 28, 2015
    Publication date: August 6, 2015
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • Patent number: 8815888
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: August 26, 2014
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • Publication number: 20140235595
    Abstract: Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein.
    Type: Application
    Filed: September 4, 2013
    Publication date: August 21, 2014
    Applicant: Aptuit, Inc.
    Inventors: Ekaterina ALBERT, Patricia ANDRES, Melanie Janelle BEVILL, Jared SMIT, Jennifer NELSON
  • Patent number: 8754098
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: June 17, 2014
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston